Akademik Veri Yönetim Sistemi
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.2, ss.1-8, 2026 (SCI-Expanded, Scopus)
Introduction: Escherichia
coli is among the most common causes of urinary tract infections
(UTIs), and the rise in extended-spectrum
beta-lactamase (ESBL)-producing isolates is a growing concern because of
increasingly limited treatment options. This study aimed to investigate the
resistance profiles of ESBL-positive and -negative uropathogenic E. coli isolates to antibiotics used in
treatment and colistin.
Methodology: Urine samples sent to the Central Laboratory of Istanbul
University, Istanbul Faculty of Medicine, for routine examination between
September 2023 and January 2024 were included in the study. The presence of
ESBL and susceptibility to antibiotics other than colistin were determined by
the Vitek2 (bioMérieux, France) automated system, and colistin susceptibility
was determined by the reference broth microdilution method.
Results: Of the 80 patients
with E. coli, 80% were female, and 20% were male; 32.5% were children,
and 67.5% were adults. All E. coli
isolates were susceptible to nitrofurantoin, ertapenem, and meropenem. 40% of
the strains were ESBL-positive. In respect of multidrug-resistant bacteria,
among ESBL-positive and-negative isolates, 12.5% and 2.1% were resistant to
six, 28.1% and 8.3% to five, 34.4% and 6.25% to four, and 18.75% and 16.7% to
three different antibiotic groups, respectively. Of 80 E. coli strains,
92.5% of which were sensitive to colistin, the MIC50 value was 0.5
mg/L, and the MIC90 value was 2 mg/L.
Conclusions: Although the
colistin resistance rate and minimum inhibitory concentration (MIC) values are
not high, it is important to monitor resistance when treating problematic
infections with multiple resistance.